Literature DB >> 24552693

Changes of oscillatory activity in the subthalamic nucleus during obsessive-compulsive disorder symptoms: two case reports.

Julien Bastin1, Mircea Polosan2, Brigitte Piallat3, Paul Krack4, Thierry Bougerol5, Stéphan Chabardès6, Olivier David3.   

Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has positive and negative effects on mood and cognition, as shown in patients suffering from Parkinson's disease (PD) and severe obsessive-compulsive disorders (OCD). Such behavioural and clinical effects suggest that the STN has an important function in limbic circuitry, which still needs to be clarified from electrophysiological recordings. Here we report two exceptional cases of OCD patients in whom local field potentials (LFP) of the anterior STN were directly recorded during acute obsessive-compulsive symptoms. We found significant symptom-related changes in different frequency bands, with no clear preferential oscillatory pattern. The overall modified STN activity during OCD symptoms suggests a mixture of both pathological and compensatory mechanisms that would reflect the maintenance of an over stable motor/cognitive/emotional set. Whether this activity propagates throughout the entire cognitive-limbic loops that are impaired in OCD is an interesting question for future research in larger series of patients.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Deep brain stimulation; Obsessive-compulsive disorders; Oscillations; Subthalamic nucleus

Mesh:

Year:  2014        PMID: 24552693     DOI: 10.1016/j.cortex.2013.12.007

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  8 in total

Review 1.  Mechanisms of deep brain stimulation.

Authors:  Todd M Herrington; Jennifer J Cheng; Emad N Eskandar
Journal:  J Neurophysiol       Date:  2015-10-28       Impact factor: 2.714

Review 2.  Toward Electrophysiology-Based Intelligent Adaptive Deep Brain Stimulation for Movement Disorders.

Authors:  Andrea A Kühn; R Mark Richardson; Wolf-Julian Neumann; Robert S Turner; Benjamin Blankertz; Tom Mitchell
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

3.  Subthalamic local field potentials in Parkinson's disease and isolated dystonia: An evaluation of potential biomarkers.

Authors:  Doris D Wang; Coralie de Hemptinne; Svjetlana Miocinovic; Salman E Qasim; Andrew M Miller; Jill L Ostrem; Nicholas B Galifianakis; Marta San Luciano; Philip A Starr
Journal:  Neurobiol Dis       Date:  2016-02-14       Impact factor: 5.996

4.  Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond.

Authors:  Walid Bouthour; Pierre Mégevand; John Donoghue; Christian Lüscher; Niels Birbaumer; Paul Krack
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

Review 5.  Clinical Outcome and Mechanisms of Deep Brain Stimulation for Obsessive-Compulsive Disorder.

Authors:  Maarten van Westen; Erik Rietveld; Martijn Figee; Damiaan Denys
Journal:  Curr Behav Neurosci Rep       Date:  2015

6.  Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder.

Authors:  Pnina Rappel; Odeya Marmor; Atira S Bick; David Arkadir; Eduard Linetsky; Anna Castrioto; Idit Tamir; Sara A Freedman; Tomer Mevorach; Moran Gilad; Hagai Bergman; Zvi Israel; Renana Eitan
Journal:  Transl Psychiatry       Date:  2018-06-18       Impact factor: 6.222

7.  Spatio-molecular domains identified in the mouse subthalamic nucleus and neighboring glutamatergic and GABAergic brain structures.

Authors:  Sylvie Dumas; Maria Papathanou; Åsa Wallén-Mackenzie; Mihaela M Martis Thiele; Bianca Vlcek; Niclas König; Åsa K Björklund
Journal:  Commun Biol       Date:  2020-07-03

8.  Modulation of motor inhibition by subthalamic stimulation in obsessive-compulsive disorder.

Authors:  A Kibleur; G Gras-Combe; D Benis; J Bastin; T Bougerol; S Chabardès; M Polosan; O David
Journal:  Transl Psychiatry       Date:  2016-10-18       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.